Business context and reporting period
The supplied filing is Nemus Bioscience, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2016, signed May 13, 2016. The request metadata identifies Skye Bioscience, Inc.; that does not match the registrant named in the filing. Verify the company and filing before relying on this summary.
Nemus is a pre-revenue biopharmaceutical company developing cannabinoid-based therapeutics with the University of Mississippi. It reported no revenue from planned principal operations.
Financial and operating highlights
| Metric | Q1 2016 | Q1 2015 or comparison |
|---|---|---|
| Revenue | $0 | $0; no revenue generated since inception |
| Research and development expense | $135,358 | $37,200 |
| General and administrative expense | $1,084,981 | $872,625 |
| Total operating expenses / operating loss | $1,220,339 / ($1,220,339) | $909,825 / ($909,825) |
| Net loss | ($1,685,447) | ($910,225) |
| Basic and diluted loss per share | ($0.08) | ($0.06) |
| Cash used in operating activities | ($1,148,471) | ($751,694) |
Operating expenses increased about 34%, while net loss increased about 85%. The 2016 net loss included $464,708 of non-operating expense from remeasurement of Series B warrant and preferred-stock conversion liabilities; 2015 had no comparable charge. With no revenue, profit margins are not meaningful.
Cash and cash equivalents were $2,061,622 at March 31, 2016, down from $3,221,209 at December 31, 2015. Current assets were $2,284,844 and current liabilities were $490,018, implying working capital of approximately $1.79 million. Total liabilities were $3,359,701, including a $2,866,439 Series B warrant liability. The filing does not report conventional interest-bearing debt. Series B preferred stock had a $4.5 million liquidation preference and contingent redemption provisions.
Material changes, outlook, and risks
- R&D spending rose as the company incurred University of Mississippi CIPN research costs and contract-manufacturer process and analytical development costs. The filing reports $36,600 of CMO fees recognized in the quarter and $18,536 for CIPN research.
- Management expects continuing losses and significant R&D, public-company, legal, accounting, staffing, and equipment costs. It stated that, without additional funding, available funds would not be sufficient to meet obligations within one year after issuance of the financial statements, creating substantial doubt about the company’s ability to continue as a going concern.
- Management plans to seek equity or debt financing, collaborations, licensing arrangements, asset sales, grants, or other funding, but gave no assurance of availability. Equity funding may dilute shareholders; debt or senior securities may restrict operations. Funding shortfalls could force spending reductions, delays, program curtailment, or relinquishment of asset rights.
- Development programs include UM5050, a THC pro-drug being developed for glaucoma and other delivery routes; UM8930, a CBD pro-drug; and research into MRSA and chemotherapy-induced peripheral neuropathy. The UM licenses include potential aggregate milestone payments of $2.1 million for UM5050 and $1.4 million for UM8930, plus royalties and patent-cost reimbursement.
- A former CEO sued the company and its Executive Chairman over his termination, seeking unspecified damages and fees. The company disputes the allegations and says it will pursue its own claims. The filing states that an unfavorable outcome could adversely affect operations or financial condition.
- Key risks include early-stage research and regulatory uncertainty, dependence on the University of Mississippi and third parties, the need for substantial additional capital, intellectual-property protection, and the complex regulatory framework for cannabis in the United States. Management reported no material changes to previously disclosed risk factors and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm that this Nemus Bioscience filing—not a Skye Bioscience filing—is the intended document.
- Assess current cash needs and financing prospects against management’s going-concern warning; the filing provides no committed new financing.
- Review the Series B preferred-stock redemption triggers, down-round protections, warrant liability valuation, and potential dilution.
- Check progress, costs, milestones, and licensing terms for the UM programs and CMO development work.
- Track the former CEO litigation and any subsequent developments or potential financial exposure.